« Back to Record
Citation APA

Hiltermann, J., Izumi, H., Cho, B., Cunha, S., Danchaivijitr, P., Felip, E., Ho, G., Leventakos, K., Li, Y., Sugawara, S., Voon, P.-J., Wauters, E., Yang, T.-Y., Brandão, M., Chen, H., Achour, I., Colebrook, S., Sone, K., Bhulani, N., Karanovic, D., & Wang, Y. (2024). OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%. Journal of Thoracic Oncology, 19(10), S33. doi:10.1016/j.jtho.2024.09.061


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401698

Hiltermann, J., Izumi, H., Cho, B., Cunha, S., Danchaivijitr, P., Felip, E., Ho, G., Leventakos, K., Li, Y., Sugawara, S., Voon, P.-J., Wauters, E., Yang, T.-Y., Brandão, M., Chen, H., Achour, I., Colebrook, S., Sone, K., Bhulani, N., Karanovic, D., & Wang, Y. (2024). OA11.03 Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%. Journal of Thoracic Oncology, 19(10), S33. doi:10.1016/j.jtho.2024.09.061